The effects of pentazocine, a kappa agonist, in patients with mania

International Journal of Neuropsychopharmacology

Volumn 11, Issue 2, 2008, Pages 243-247

  Cohen, Bruce M ^a   Murphy, Beth ^b  

^a MCLEAN HOSPITAL   (United States)

^b NONE

Author keywords

Bipolar disorder; Kappa agonist; Mania; Pentazocine; Treatment effects

Indexed keywords

ARIPIPRAZOLE; CARBAMAZEPINE; CLONAZEPAM; KAPPA OPIATE RECEPTOR AGONIST; LAMOTRIGINE; LITHIUM; LORAZEPAM; NALOXONE; OLANZAPINE; PENTAZOCINE; PERPHENAZINE; QUETIAPINE; RISPERIDONE; VALPROIC ACID;

ADULT; AGED; ARTICLE; BIPOLAR I DISORDER; CLINICAL ARTICLE; CONTROLLED STUDY; DIZZINESS; DRUG EFFECT; FEMALE; HUMAN; MALE; MANIA; PRIORITY JOURNAL; SCORING SYSTEM; SEDATION; SIDE EFFECT; STOMACH DISCOMFORT; SYMPTOMATOLOGY; TREATMENT OUTCOME;

ADULT; AFFECT; ANTIMANIC AGENTS; BIPOLAR DISORDER; DRUG ADMINISTRATION SCHEDULE; FEMALE; HUMANS; INPATIENTS; MALE; MIDDLE AGED; PENTAZOCINE; PSYCHIATRIC STATUS RATING SCALES; RECEPTORS, OPIOID, KAPPA; TREATMENT OUTCOME; WAKEFULNESS;

EID: 38949162571     PISSN: 14611457     EISSN: 14695111     Source Type: Journal    
DOI: 10.1017/S1461145707008073     Document Type: Article

References (25)

1. Barber A, Gottschlich R (1997). Novel developments with selective, non-peptidic kappa-opioid receptor agonists. Expert Opinion on Investigational Drugs 6, 1351-1368.
2. Bidlack JM, McLaughlin JP, Wentland MP (2000). Partial opioids: medications for the treatment of pain and drug abuse. Annals of the New York Academy of Science 909, 1-11.
3. Bowen CA, Negus SS, Zong R, Neumeyer JL, Bidlack JM, Mello NK (2003). Effects of mixed κ/μ opioids on cocaine self-administration and cocaine discrimination by rhesus monkeys. Neuropsychopharmacology 28, 1125-1139.
4. Carlezon Jr. WA, Beguin C, DiNieri J, Baumann MH, Richards M, Todtenkopf MS, Rothman RB, Ma Z, Lee DY-L, Cohen BM (2006). Depressive-like effects of the k-opioid receptor agonist Salvinorin A on behavior and neurochemistry in rats. Journal of Pharmacology and Experimental Therapeutics 314, 440-447.
5. Carlezon WA, Cohen BM (In Press). Kappa agents in the treatment of mood disorders. In: Dean RL, Bilsky EJ, Negus III SS (Eds.), Opioid Receptors and Antagonists: From Bench to Clinic (volume in the Contemporary Neuroscience series).
6. Cohen BM, Lipinski JF (1986). Treatment of acute psychosis with non-neuroleptic agents. Psychosomatics (Suppl.) 27, 7-16.
7. Davis KL, Berger PA, Hollister LE, Defraites E (1978). Physostigmine in mania. Archives of General Psychiatry 35, 119-122.
8. DiChiara G, Imperato A (1988). Opposite effects of mu and kappa opiate agonists on dopamine release in the nucleus accumbens and in the dorsal caudate of freely moving rats. Journal of Pharmacology and Experimental Therapeutics 244, 1067-1080.
9. Gonzalez D, Riba J, Bouso JC, Gomes-Jarabo G, Barbanoj MJ (2006). Pattern of use and subjective effects of Salvia divinorum among recreational users. Drug and Alcohol Dependence 85, 157-162.
10. IsHak WW, Burt T, Sederer LI (2002). Outcome Measurement in Psychiatry. Washington DC: American Psychiatric Press.
11. Jackisch R, Geppert M, Illes P (1986). Characterization of opioid receptors modulating noradrenaline release in the hippocampus of the rabbit. Journal of Neurochemistry 46, 1802-1810.
12. Janowsky DS, El-Yousef MK, Davis JM, Sekerke HJ (1973). Parasympathetic suppression of manic symptoms by physostigmine. Archives of General Psychiatry 28, 542-547.
13. Keck PE, Cohen BM, Baldessarini RJ, McElroy SL (1989). Time course of antipsychotic effects of neuroleptic drugs. American Journal of Psychiatry 146, 1289-1292.
14. Ma J, Ye N, Lange N, Cohen BM (2003). Dynorphinergic GABA neurons are a target of both typical and atypical antipsychotic drugs in the nucleus accumbens shell, central amygdaloid nucleus and thalamic central medial nucleus. Neuroscience 121, 991-998.
15. Mague SD, Pilakas AM, Todtenkopf MS, Tomasiewicz HC, Zhang Y, Stevens Jr. WC, Jones RM, Portoghese PS, Carlezon Jr. WA (2003). Antidepressant-like effects of k-opioid receptor antagonists in the forced swim test in rats. Journal of Pharmacology and Experimental Therapeutics 305, 323-330.
16. Manzanares J, Lookingland KJ, Moore KE (1991). Kappa opioid receptor-mediated regulation of dopaminergic neurons in the rat brain. Journal of Pharmacology and Experimental Therapeutics 226, 500-505.
17. Pfeiffer A, Brantl V, Herz A, Emrich HM (1986). Psychotomimesis mediated by k opiate receptors. Science 233, 774-775.
18. Phrolov K, Applebaum J, Levine J, Miodovnick H, Belmaker RH (2004). Single-dose intravenous valproate in acute mania. Journal of Clinical Psychiatry 65, 68-70.
19. Roth BL, Baner K, Westkaemper R, Siebert D, Rice KC, Steinberg S, Ernsberger P, Rothman RB (2002). Salvinorin A: a potent naturally occurring non-nitrogenous kappa opioid selective agonist. Proceedings of the National Academy of Sciences USA 99, 11934-11939.
20. Sinonin F, Gaveriaux-Ruff C, Befort K, Matthes H, Lannes B, Micheletti G, Mattei M-G, Charron G, Bloch B, Kieffer B (1995). κ-Opioid receptor in humans: cDNA and genomic cloning, chromosomal assignment, functional expression, pharmacology, and expression pattern in the central nervous system. Proceedings of the National Academy of Sciences USA 92, 7006-7010.
21. Wald D, Ebstein P, Belmaker RH (1978). Haloperidol and lithium blocking of the mood response to intravenous methylphenidate. Psychopharmacology 57, 83-87.
22. Walsh SL, Strain EC, Abreu ME, Bigelow GE (2001). Enadoline, a selective kappa opioid agonist: comparison with butorphanol and hydromorphone in humans. Psychopharmacology 157, 151-162.
23. Young RC, Biggs JT, Ziegler VE, Meyer DA (1978). A rating scale for mania: reliability, validity and sensitivity. British Journal of Psychiatry 133, 429-435.
24. 35S]GTPγS binding to membranes: determination of potencies and efficacies of ligands: Journal of Pharmacology and Experimental Therapeutics 282, 676-684.
25. Zubenko GS, Cohen BM, Lipinski JF, Jonas JM (1984). Clonidine in the treatment of bipolar disorder. American Journal of Psychiatry 141, 1617-1618.